Halaven (eribulin mesylate) / Eisai 
Welcome,         Profile    Billing    Logout  
 71 Diseases   100 Trials   100 Trials   2706 News 


«12...1011121314151617181920...3738»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  SAKK 25/14: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Sep 29, 2021   
    P2,  N=78, Terminated, 
    Trial completion date: Oct 2023 --> Jul 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Dec 2020; The trial was prematurely terminated as of 22.07.2021 as per SAKK board decision board decision from 14th of November 2020. The trial was terminated after the primary endpoint was analyzed, which was the case end of December 2020.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal:  PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. (Pubmed Central) -  Sep 29, 2021   
    The trial was terminated after the primary endpoint was analyzed, which was the case end of December 2020. PI3K pathway activation induces primary resistance or early adaptation to eribulin, supporting the combination of PI3K inhibitors and eribulin for the treatment of HER2- BC patients.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date, Surgery:  Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 24, 2021   
    P1,  N=23, Completed, 
    PI3K pathway activation induces primary resistance or early adaptation to eribulin, supporting the combination of PI3K inhibitors and eribulin for the treatment of HER2- BC patients. Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Jul 2021
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Preclinical, Journal:  TP53 null mutations identify lung cancer cell lines with highest sensitivity to the non-taxane microtubule inhibitor, eribulin. (Pubmed Central) -  Sep 24, 2021   
    Significance Statement Distinct from precision oncology agents that are matched to cancers bearing oncogenically-activated versions of their targets, microtubule inhibitors such as eribulin are deployed in an unselected manner. The results in this study demonstrate that lung cancer cell lines exhibiting the highest sensitivity to eribulin bear TP53 null phenotypes, supporting a rationale to consider the status of this tumor suppressor in the clinical setting.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    [VIRTUAL] Exploring MORAb-109: A Site-Specific Eribulinconjugated ADC Targeting Human Mesothelin () -  Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_100;    
    The results in this study demonstrate that lung cancer cell lines exhibiting the highest sensitivity to eribulin bear TP53 null phenotypes, supporting a rationale to consider the status of this tumor suppressor in the clinical setting. MORAb-109 is a humanized DAR2 eribulin-conjugated ADC targeting human mesothelin that utilizes Eisai’s proprietary RESPECT-L technology Evaluate how, in preclinical in vivo studies, MORAb-109 demonstrated dose-dependent anti-tumor activity, with regression observed in multiple patient-derived xenograft models including models with heterogeneous mesothelin expression Discover how MORAb-109 exhibited stability in vivo in rodent and non-human primate species, and is being considered for further development as a targeted therapy for mesothelinexpressing tumors
  • ||||||||||  imatinib / Generic mfg., ifosfamide / Generic mfg., docetaxel / Generic mfg.
    Journal:  Treatment of soft tissue sarcomas including GIST - Update 2021 (Pubmed Central) -  Sep 22, 2021   
    Ripretinib has shown very promising activity in forth and further lines of therapy and is already approved in the US. The use of adjuvant imatinib therapy in patients with completely resected localized GIST with a high risk of recurrence has significantly improved overall survival with a treatment duration of 3 years. These results have now been confirmed with a 10 years follow-up analysis.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Clinical, Journal:  Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. (Pubmed Central) -  Sep 15, 2021   
    The combination reduced pharmacodynamic markers indicative of single agent mechanisms, but in tumors dramatically activated the TP53 pathway. Although a mechanism for in vivo synergy requires further study, it is possible that eribulin-induced inhibition of microtubule dynamics enhances irinotecan-induced nuclear accumulation of TP53, leading to rapid cell death.
  • ||||||||||  paclitaxel trevatide (ANG1005) / Angiochem
    Trial completion date, Trial primary completion date:  ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) -  Sep 9, 2021   
    P3,  N=150, Not yet recruiting, 
    Although a mechanism for in vivo synergy requires further study, it is possible that eribulin-induced inhibition of microtubule dynamics enhances irinotecan-induced nuclear accumulation of TP53, leading to rapid cell death. Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Jun 2023
  • ||||||||||  Review, Journal:  Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. (Pubmed Central) -  Sep 9, 2021   
    Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  KORNELIA: Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Sep 8, 2021   
    P1/2,  N=90, Active, not recruiting, 
    Eribulin-trastuzumab combination is an effective and safe treatment option with a low toxicity profile for aggressively pre-treated patients with metastatic breast cancer. Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Apr 2022
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal:  Unravelling the therapeutic potential of marine drugs as SARS-CoV-2 inhibitors: An insight from essential dynamics and free energy landscape. (Pubmed Central) -  Sep 8, 2021   
    The results of the binding affinity studies showed that two compounds, eribulin mesylate (eri) and soblidotin (sob), displayed higher docking scores than did the reference compound...Furthermore, the essential dynamics and free energy landscape exploration revealed that the protein had navigated through a minimal energy basin and demonstrated favourable conformation while binding to the proposed inhibitors. Collectively, our findings suggest that two marine compounds, namely eri and sob, show potential as SARS-CoV-2 main protease inhibitors.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Enrollment change, Trial completion date, Trial termination, Monotherapy, Metastases:  REVERT: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (clinicaltrials.gov) -  Aug 31, 2021   
    P2,  N=22, Terminated, 
    Thus, these suggest eribulin may be a first-line treatment candidate for patients with HER2-negative advanced breast cancer in Japan. N=60 --> 22 | Trial completion date: Sep 2021 --> Mar 2021 | Recruiting --> Terminated; Slow recruitment rate
  • ||||||||||  ifosfamide / Generic mfg.
    Clinical, Clinical data, Journal:  Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan. (Pubmed Central) -  Aug 8, 2021   
    Since 2012, physicians were able to administer second- and/or third-line treatment easily in Japan, following the approval of new drugs, namely, pazopanib, eribulin, and trabectedin...As first-line treatment, doxorubicin and ifosfamide and other drugs were administered to 7 and 27 patients, respectively...New drugs may be beneficial for patients with advanced STS. When patients cannot receive anthracycline-based chemotherapy because of a high risk of side effects, we believe that the aforementioned drugs may be administered as the first-line treatment.
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
    New P2 trial, Metastases:  Scalp Cooling in MBC (clinicaltrials.gov) -  Aug 3, 2021   
    P2,  N=120, Not yet recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Combination therapy, IO biomarker, Metastases:  Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) -  Jul 27, 2021   
    P2,  N=46, Active, not recruiting, 
    Recruiting --> Completed | N=111 --> 40 | Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021 Recruiting --> Active, not recruiting
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, PARP Biomarker:  Development and validation of an LC-MS/MS generic assay platform for small molecule drug bioanalysis. (Pubmed Central) -  Jul 23, 2021   
    Eribulin monotherapy or plus other agents is an alternative for the heavily pretreated patients with MBC. The generic approach has become a useful tool to further define the pharmacology of drugs studied in our laboratory and may be utilized as described, or as starting point to develop drug-specific assays with more extensive performance characterization.
  • ||||||||||  ipatasertib (GDC-0068) / Roche, Halaven (eribulin mesylate) / Eisai
    [VIRTUAL] Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_1718;    
    P2a
    Pathfinder is evaluating the safety, tolerability, and preliminary efficacy of ipatasertib in combination with non-taxane chemotherapy agents in taxane-pretreated unresectable advanced TNBC.Trial designThis is a multicenter, open-label, non-comparative, phase IIa trial with a safety run-in. Main selection criteria include: (a) Female pts with taxane-pretreated unresectable locally advanced or metastatic TNBC amenable to biopsy; (b) At least 1 and up to 2 prior chemotherapeutic regimens in metastatic setting; (c) No prior treatment with PI3K, mTOR, and/or AKT inhibitors; (d) Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • ||||||||||  balixafortide (POL 6326) / Polyphor, Halaven (eribulin mesylate) / Eisai, lonodelestat (POL6014) / Santhera, Cold Spring Harbor Laboratory
    Journal:  Macrocycle Therapeutics to Treat Life-threatening Diseases. (Pubmed Central) -  Jul 16, 2021   
    Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.